Clinical selection criteria for treatment of HD IL2
| Clinical Selection criteria: | |
| • Histological diagnosis of clear-cell type metastatic renal cell carcinoma with measurable disease • Performance status 0–1 • Prior-nephrectomy • No concomitant use of steroids • No evidence of active CNS involvement • No history of coronary artery disease or normal stress echocardiogram for patient older than 55-year-old of age. |